We focus on the development of a wide variety of therapeutic monoclonal antibody products that provide medically differentiated therapies in cancers and the treatment of autoimmune diseases, which, according to Frost & Sullivan, are among the largest therapeutic areas in the monoclonal antibody segment, with an aggregate market size of RMB10.4 billion in 2017 and an expected aggregate market size of RMB64.6 billion in 2022.

We have efficient R & D capabilities, extensive and advanced preparation technology and low-cost drug production capacity, with a view to provide high-quality and reasonably priced innovative biopharmaceutical products to patients in China and other emerging markets.

In our product pipeline, CMAB008 (infliximab) has been approved for marketing, the new drug application (NDA) of CMAB007 (omalizumab) has been accepted, CMAB009 (cetuximab) and CMAB807 (denosumab) are in phase III clinical trial, and CMAB819 (nivolumab) is in phase I clinical trial. In addition, we also have several other drugs in preclinical R & D stage.